Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00410761
Registration number
NCT00410761
Ethics application status
Date submitted
6/12/2006
Date registered
13/12/2006
Date last updated
2/10/2023
Titles & IDs
Public title
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Query!
Scientific title
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Query!
Secondary ID [1]
0
0
2005-005077-29
Query!
Secondary ID [2]
0
0
D4200C00058
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Thyroid Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Thyroid
Query!
Cancer
0
0
0
0
Query!
Neuroendocrine tumour (NET)
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other endocrine disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ZD6474 (Vandetanib)
No Intervention: 1 - Placebo vandetanib
Experimental: 2 - Vandetanib
Treatment: Drugs: ZD6474 (Vandetanib)
once daily oral tablet
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival(PFS)
Query!
Assessment method [1]
0
0
Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.
Query!
Timepoint [1]
0
0
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.
The categories for best objective response are CR, PR, stable disease (SD)>= 12 weeks, progressive disease (PD) or NE.
Query!
Timepoint [1]
0
0
RECIST assessments performed at screening (within 3 weeks before randomisation), then every 12 weeks. For patients with objective response of CR or PR, an additional confirmatory scan was performed =4 weeks following the date of first response.
Query!
Secondary outcome [2]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [2]
0
0
Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) >= 12 weeks
Query!
Timepoint [2]
0
0
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent
Query!
Secondary outcome [3]
0
0
Duration of Response (DoR)
Query!
Assessment method [3]
0
0
Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met
Query!
Timepoint [3]
0
0
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
As data was immature at data cut off, number of death events is quoted
Query!
Timepoint [4]
0
0
Number of deaths since randomisation
Query!
Secondary outcome [5]
0
0
Biochemical Response Calcitonin (CTN)
Query!
Assessment method [5]
0
0
Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CTN.
Query!
Timepoint [5]
0
0
Blood samples Blood samples for analysis of CTN were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up
Query!
Secondary outcome [6]
0
0
Biochemical Response Carcinoembryonic Antigen (CEA)
Query!
Assessment method [6]
0
0
Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CEA.
Query!
Timepoint [6]
0
0
Blood samples for analysis of CEA were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up
Query!
Secondary outcome [7]
0
0
Time to Worsening of Pain (TWP)
Query!
Assessment method [7]
0
0
TWP was derived using the worst pain score from brief pain inventory (BPI) and patient reported opioid analgesic use. BPI uses 0 to 10 numeric rating scales asking subjects to rate their pain.
Query!
Timepoint [7]
0
0
During the last week of the screening period (Day -7 to Day 0), the brief pain inventory (BPI) and opioid analgesic use were self-reported once a day for 4 days to establish baseline, then every week during blinded study treatment, up to discontinuation.
Query!
Eligibility
Key inclusion criteria
- Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or
sporadic Medullary Thyroid Cancer.
- Presence of measurable tumor
- Able to swallow medication
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Major surgery within 4 weeks before randomization
- Last dose of prior chemotherapy received less than 4 weeks prior to randomization
- Radiation therapy within the last 4 weeks prior to randomization(with exception of
palliative radiotherapy)
- Brain metastases or spinal cord compression, unless treated at least 4 weeks before
first dose and stable without steroid treatment for 10 days
- Significant cardiac events
- Previous ZD6474 treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/11/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
28/06/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
437
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 1001 - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Vermont
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Wien
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Leuven
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Porto Alegre
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Ribeirão Preto
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Calgary
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
London
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Moncton
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Sherbrooke
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Toronto
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Praha 5
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Odense C
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
BORDEAUX Cedex
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
LYON Cedex 8
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Villejuif
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Essen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Halle
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Würzburg
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Pécs
Query!
Country [36]
0
0
India
Query!
State/province [36]
0
0
Mumbai
Query!
Country [37]
0
0
India
Query!
State/province [37]
0
0
Vellore
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Catania
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Milano
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Napoli
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Pisa
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Roma
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Siena
Query!
Country [44]
0
0
Korea, Republic of
Query!
State/province [44]
0
0
Seoul
Query!
Country [45]
0
0
Mexico
Query!
State/province [45]
0
0
Cd. Madero
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Mexico City
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
México
Query!
Country [48]
0
0
Netherlands
Query!
State/province [48]
0
0
Groningen
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Utrecht
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Gliwice
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Poznan
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Warszawa
Query!
Country [53]
0
0
Portugal
Query!
State/province [53]
0
0
Coimbra
Query!
Country [54]
0
0
Portugal
Query!
State/province [54]
0
0
Lisboa
Query!
Country [55]
0
0
Romania
Query!
State/province [55]
0
0
Bucarest
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Obninsk
Query!
Country [57]
0
0
Serbia
Query!
State/province [57]
0
0
Belgrade
Query!
Country [58]
0
0
Serbia
Query!
State/province [58]
0
0
Belgrad
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Madrid
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Pamplona
Query!
Country [61]
0
0
Sweden
Query!
State/province [61]
0
0
Stockholm
Query!
Country [62]
0
0
Sweden
Query!
State/province [62]
0
0
Uppsala
Query!
Country [63]
0
0
Switzerland
Query!
State/province [63]
0
0
Basel
Query!
Country [64]
0
0
Switzerland
Query!
State/province [64]
0
0
Bern
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genzyme, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer
patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body,
about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00410761
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00410761
Download to PDF